Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Natalucci

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Life (Basel, Switzerland)|April 28, 2023
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive StudyFulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, et al.
Immunologic Research|October 1, 2024
Belimumab 10 years later: how drug positioning has changedFulvia Ceccarelli, Francesco Natalucci, Claudia Ciancarella, et al.
Lupus|October 20, 2021
Erosive arthritis in systemic lupus erythematosus: not only RhupusFulvia Ceccarelli, Francesco Natalucci, Giulio Olivieri, et al.
Autoimmunity Reviews|June 10, 2023
Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenonFulvia Ceccarelli, Carlo Perricone, Francesco Natalucci, et al.
Clinical and Experimental Rheumatology|October 28, 2022
Erosive arthritis in systemic lupus erythematosus: application of cluster analysisFulvia Ceccarelli, Francesco Natalucci, Carmelo Pirone, et al.
Lupus|January 6, 2023
Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with BelimumabIlaria Schiavoni, Eleonora Olivetta, Francesco Natalucci, et al.
Journal of Immunology Research|April 28, 2023
Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease ActivityFulvia Ceccarelli, Francesco Natalucci, Alessandra Di Filippo, et al.
Arthritis Research & Therapy|September 30, 2025
Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohortFrancesco Natalucci, Clément Triaille, Emilie Sapart, et al.
The Israel Medical Association Journal : IMAJ|November 25, 2020
Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal StudyFulvia Ceccarelli, Enrica Cipriano, Francesco Natalucci, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Fever in systemic lupus erythematosus: associated clinical features and genetic factorsGiulio Olivieri, Fulvia Ceccarelli, Carlo Perricone, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Life (Basel, Switzerland)|April 28, 2023
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive StudyFulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, et al.
Immunologic Research|October 1, 2024
Belimumab 10 years later: how drug positioning has changedFulvia Ceccarelli, Francesco Natalucci, Claudia Ciancarella, et al.
Lupus|October 20, 2021
Erosive arthritis in systemic lupus erythematosus: not only RhupusFulvia Ceccarelli, Francesco Natalucci, Giulio Olivieri, et al.
Autoimmunity Reviews|June 10, 2023
Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenonFulvia Ceccarelli, Carlo Perricone, Francesco Natalucci, et al.
Clinical and Experimental Rheumatology|October 28, 2022
Erosive arthritis in systemic lupus erythematosus: application of cluster analysisFulvia Ceccarelli, Francesco Natalucci, Carmelo Pirone, et al.
Lupus|January 6, 2023
Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with BelimumabIlaria Schiavoni, Eleonora Olivetta, Francesco Natalucci, et al.
Journal of Immunology Research|April 28, 2023
Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease ActivityFulvia Ceccarelli, Francesco Natalucci, Alessandra Di Filippo, et al.
Arthritis Research & Therapy|September 30, 2025
Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohortFrancesco Natalucci, Clément Triaille, Emilie Sapart, et al.
The Israel Medical Association Journal : IMAJ|November 25, 2020
Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal StudyFulvia Ceccarelli, Enrica Cipriano, Francesco Natalucci, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Fever in systemic lupus erythematosus: associated clinical features and genetic factorsGiulio Olivieri, Fulvia Ceccarelli, Carlo Perricone, et al.
Pageof 4